SGEN Related StreetInsider.com Reports
-
Seattle Genetics Inc. (SGEN) Tops Q1 EPS by 6c
-
Goldman Sachs Resumes Seattle Genetics (SGEN) at Neutral
-
Trading Radar for 05/07: Electronic Arts (EA), DirecTV (DTV), Fossil (FOSL), McKesson (MCK) Report
-
Seattle Genetics (SGEN) Submits sBLA to FDA for Broader ADCETRIS Usage
-
StreetInsider.com Notable Analyst Rating Changes 02/13: (GRPN) (NNA) (UTIW) Upgraded; (FOSL) (SGEN) (SAPE) Downgraded
-
Needham & Company Downgrades Seattle Genetics (SGEN) to Hold
-
Seattle Genetics (SGEN) in Focus After Tops Q4 EPS by 2c, Provides Outlook
-
Trading Radar for 02/12: McGraw-Hill (MHP), Clearwire (CLWR), Michael Kors (KORS), Coca-Cola (KO), Avon Products (AVP) Report
-
Seattle Genetics' (SGEN) ADCETRIS Approved by Health Canada
-
Seattle Genetics (SGEN), Millennium Initiate ADCETRIS Phase III
-
Seattle Genetics (SGEN) Updates on Select ADC Programs by Roche's (RHHBY) Genentech
-
Seattle Genetics (SGEN) Updates on ADCETRIS in Relapsed HL
-
Seattle Genetics (SGEN) granted FDA orphan drug status for Mycois Fungoides
-
Credit Suisse Starts Seattle Genetics (SGEN) at Outperform
-
Guggenheim Starts Seattle Genetics (SGEN) at Neutral
-
StreetInsider.com Pre-Open Movers 11/08: (DUSA) (WLL) (QCOM) Higher; (BCRX) (PANL) (SGEN) Lower (more...)
-
Cantor Fitzgerald Downgrades Seattle Genetics (SGEN) to Sell
-
Seattle Genetics Inc. (SGEN) Tops Q3 EPS by 3c
-
Seattle Genetics (SGEN) Medical Chief Reynolds to Resign
-
Seattle Genetics (SGEN) AADCETRIS® Receives EC Conditional Marketing Authorization
-
Seattle Genetics (SGEN) Expands ADC Collaboration w/ Abbott (ABT); Will Get $25M Upfront
-
Seattle Genetics (SGEN) Initiates ADCETRIS Phase II in New HL Patents Over 60
-
Millennium, Seattle Gen (SGEN) Updates on Sequential Therapy with Brentuximab Vedotin in Newly Diagnosed Patients with Systemic Anaplastic Large Cell Lymphoma
-
Seattle Genetics (SGEN) and Millennium Complete Enrollment for Phase III AETHERA Trial of ADCETRIS
-
UBS on U.S. Biotechnology - Updating Outlook on Covered Stocks (GILD, AMGN, BIIB, CELG, INCY, IDIX, VRTX, SGEN)
-
Notable Analyst Rating Changes 09/07: (BCS) (RKT) (PTEN) Upgraded; (NVDA) (WY) (SGEN) Downgraded
-
UPDATE: Oppenheimer Downgrades Seattle Genetics (SGEN) to Perform; Valuation Call
-
Seattle Genetics Inc. (SGEN) Reports In-Line Q2 EPS
-
Trading Radar for 08/08: Macy's (M), Orbitz Worldwide (OWW), SodaStream (SODA), SunPower (SPWR), News Corp (NWSA) Report
-
Seattle Genetics (SGEN) Says Takeda Gets Positive ADCETRIS Recommendation from CHMP
-
Needham & Company Maintains a 'Buy' on Seattle Genetics (SGEN); Q2 Preview of Adcetris Sales
-
Notable Analyst Rating Changes 07/05: (BX) (YNDX) (TKC) Upgraded; (AMD) (MT) (BAM) Downgraded
-
ThinkEquity Starts Seattle Genetics (SGEN) at Buy
-
Pre-Open Losers 7/2: (ANH) (OIIM) (IM) Lower (more...)
-
Piper Jaffray Downgrades Seattle Genetics (SGEN) to Underweight
-
Seattle Genetics (SGEN) Offers Updated Survival Data for Adcetris Trial, Says Median Overall Survival at 24 Months 65%
-
Notable 52-Week Highs and Lows of the Day 06/08: (SGEN) (NEON) (DG) High; (ANR) (ACI) (AUO) Low
-
Needham & Company Reiterates a 'Buy' on Seattle Genetics (SGEN); Raising Price Target After ASCO Meeting Review
-
Oppenheimer Comments on Seattle Genetics (SGEN) After 2012 ASCO
-
Seattle Genetics (SGEN) to Present Data from Several ADCETRIS Trials at ASCO
-
Health Canada Accepts Seattle Genetics' (SGEN) ADCETRIS NDS for REview
-
UBS Raises PT on Seattle Genetics (SGEN) on Adcetris Label Expansion Opportunities
-
Seattle Genetics (SGEN) Updates on ADCETRIS Interim Phase II Data
-
Leerink Swann Maintains an 'Outperform' on Seattle Genetics (SGEN); Modest Growth, but Opportunities in Pipeline
-
Pre-Open Movers 5/9: (SODA) (DMD) (DF) Higher; (CQB) (DVA) (STEC) Lower (more...)
-
After-Hours Movers 05/08: (DMD) (HIMX) (NILE) Higher; (STEC) (CQB) (SGEN) (GPOR) Lower
-
Seattle Genetics Inc. (SGEN) Tops Q1 EPS by 1c
-
Trading Radar for 05/08: Walt Disney (DIS), Fossil (FOSL), Wendy's (WEN), Vitamin Shoppe (VSI), OfficeMax (OMX) Report
-
Seattle Genetics (SGEN), Takeda's Millennium Announce Deal with Ventana on Companion Diagnostic for ADCETRIS
-
Seattle Genetics (SGEN) Announces Pivotal ADCETRIS Study Published in JCO
Back to SGEN Stock Lookup
